Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472847 | 1.00 | OPRL1 (0.43) | OPRL1NOS3NOS1NOS2OPRM1 | |
| SCHEMBL30586977 | 1.00 | OPRL1 (0.43) | OPRL1NOS3NOS1NOS2OPRM1 | |
| SCHEMBL22854107 | 0.84 | OPRL1 (0.36) | OPRL1NOS3NOS1NOS2OPRM1 | |
| SCHEMBL2473071 | 0.84 | OPRL1 (0.34) | OPRL1OPRM1 | |
| SCHEMBL15387102 | 0.84 | OPRL1 (0.36) | OPRL1OPRM1 | |
| SCHEMBL24141877 | 0.84 | OPRL1 (0.36) | OPRL1OPRM1METAP2CXCR4 | |
| SCHEMBL2476900 | 0.84 | OPRL1 (0.34) | OPRL1OPRM1 | |
| SCHEMBL24141895 | 0.84 | OPRL1 (0.36) | OPRL1OPRM1METAP2CXCR4 | |
| SCHEMBL19464253 | 0.83 | CHRNB2 (0.50) | OPRL1CYP2A6CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL20851551 | 0.83 | CHRNB2 (0.50) | OPRL1CYP2A6CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664617-A1 | Method of making a 2,6-diaryl piperidine derivative | Genzyme Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1809613-B1 | METHOD OF MAKING A 2,6-DIARYL PIPERIDINE DERIVATIVE | GENZYME CORP (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-1615633-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1809613-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006049764-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2006-05-11 | — | — | WO | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | OPRL1 1945/4885NOS3 2111/4885NOS1 1491/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | OPRL1 101/4885NOS3 3770/4885NOS1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.